Cross-Border Collaborations: Key Pitfalls for Asian Life Sciences Companies and How to Avoid Them

Against the backdrop of a slower M&A market, collaborations between biotech companies and pharma companies have remained robust, particularly those focusing on innovation and collaboration for value creation. According to a recent article, the scale of cross-border and domestic licensing deals in Asia has been expanding, with licensing deals becoming a sought-after business development model in China’s pharmaceutical industry. Cross-border transactions can take various forms, such as licensing…
By: Morgan Lewis
Previous Story

Amicus Briefing in Amgen v. Sanofi: The Rest of the Story

Next Story

Unveiling the Top Areas of Venture Capital Investment in 2023